NRX Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
NRX Pharmaceuticals, Inc. (NRXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 38.65 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 38.65K shares, a 10071.58% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 10.00K shares, a 100.00% increase year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 120.96K shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 143.15K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 38.65K shares 10-Q · filed 2026-08-14 | 48.65K shares derived: sum of 2 quarters · filed 2026-08-14 | 169.62K shares derived: sum of 3 quarters · filed 2026-08-14 | 169.62K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 10.00K shares 10-Q · filed 2026-08-14 | 130.96K shares derived: sum of 2 quarters · filed 2026-08-14 | 130.96K shares derived: sum of 3 quarters · filed 2026-08-14 | 131.34K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | 120.96K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | 120.96K shares derived: sum of 2 quarters · filed 2026-08-14 | 121.34K shares derived: sum of 3 quarters · filed 2026-08-14 | 126.34K shares 10-Q · filed 2026-08-14 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 380.00 shares derived: sum of 2 quarters · filed 2025-11-14 | 5.38K shares 10-Q · filed 2025-11-14 | |
| 2025-06-30 | 380.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | 5.38K shares 10-Q · filed 2025-08-18 | ||
| 2025-03-31 | 5.00K shares 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 143.15K shares 10-K · filed 2026-03-23 | |||
| 2024-09-30 | 29.60K shares 10-Q · filed 2024-11-14 | -45.94K shares derived: sum of 2 quarters · filed 2024-11-14 | 43.60K shares derived: sum of 3 quarters · filed 2024-11-14 | |
| 2024-06-30 | -75.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-14 | 14.00K shares 10-Q · filed 2024-11-14 | ||
| 2024-03-31 | 89.55K shares 10-Q · filed 2024-11-14 | |||
| 2021-03-31 | 198.40K shares 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |